Magnesium replacement does not improve insulin resistance in patients with metabolic syndrome: a 12-week randomized double-blind study.

Autor:	Lima de Souza E Silva Mde L; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil ; Universidade Salvador, UNIFACS, Salvador, Bahia, Brasil., Cruz T; Departmento de Medicina, Programa de Pos-graduacao em Medicina e Saude da Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Brasil., Rodrigues LE; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Ladeia AM; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Bomfim O; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Olivieri L; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Melo J; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Correia R; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Porto M; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil., Cedro A; Escola Bahiana de Medicina e Saude Publica, FBDC, Salvador, Bahia, Brasil.
Jazyk:	angličtina
Zdroj:	Journal of clinical medicine research [J Clin Med Res] 2014 Dec; Vol. 6 (6), pp. 456-62. Date of Electronic Publication: 2014 Sep 09.
DOI:	10.14740/jocmr1580w
Abstrakt:	Background: To evaluate the effect of magnesium (Mg) replacement on insulin resistance and cardiovascular risk factors in women with metabolic syndrome (MS) without diabetes. Methods: This 12-week clinical randomized double-blind study compared the effects of 400 mg/day of Mg with those of a placebo (n = 72) on fasting glucose, insulin, HOMA-IR, lipid profile and CRP. Mg was measured in serum (SMg) and in mononuclear cells (MMg). Results: Hypomagnesemia (SMg < 1.7 mg/dL) was seen in 23.2% of patients and intracellular depletion in 36.1% of patients. The MMg means were lower in patients with obesity (0.94 ± 0.54 μg/mg vs. 1.19 ± 0.6 μg/mg, P = 0.04), and insulin resistance (0.84 ± 0.33 μg/mg vs. 1.14 ± 0.69 µg/mg, P < 0.05). Mg replacement did not alter SMg (1.82 ± 0.14 mg/dL vs. 1.81 ± 0.16 mg/dL, P = 0.877) and tended to increment MMg (0.90 ± 0.40 μg/mg vs. 1.21 ± 0.73 μg/mg, P = 0.089). HOMA-IR did not alter in interventions nor in placebo group (3.2 ± 2.0 to 2.8 ± 1.9, P = 0.368; 3.6 ± 1.9 to 3.2 ± 1.8, respectively), neither did other metabolic parameters. Conclusion: Serum and intracellular Mg depletion is common in patients with MS; however, Mg replacement in recommended dosage did not increase significantly Mg levels, neither reduced insulin resistance or metabolic control.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu